New Delhi, Apr 19: Dr Reddy’s Laboratories (DRL) in a declaration expressed that their intense headache treatment infusion ZembraceSymTouch is presently financially accessible in the US market.
In a BSE filling, the organization said that ‘Promius Pharma LLC’, a backup of DRL declared that ZembraceSymTouch infusion is currently industrially accessible in the US.
They got an endorsement from the US Food and Drug Administration (USFDA) for ZembraceSymTouch infusion in January this year. ZembraceSymTouch is accessible as a prefilled, prepared to utilize, single measurement expendable injector.
At the season of USFDA endorsement, DRL had said the new item will be advertised in the US by Promius Pharma.
“ZembraceSymTouch is the initially marked item in the organization’s neurology portfolio,” DRL Executive Vice President Propriety Products Group, Raghav Chari said.